Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
You may also be interested in...
Several small biotechs are launching new drugs independently in a launch environment that now presents unexpected challenges caused by COVID-19.
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.